Premium
The role of midazolam and flumazenil in urology
Author(s) -
Birch B. R. P.,
Anson K.,
Gelister J.,
Parker C.,
Miller R. A.
Publication year - 1990
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1990.tb03177.x
Subject(s) - flumazenil , medicine , midazolam , sedation , anesthesia , placebo , hypnotic , benzodiazepine , receptor , alternative medicine , pathology
The effects of midazolam (3–10 mg im.) and their reversal by flumazenil were studied in transurethral endoscopic procedures performed using topical analgesia. In one randomised study, patients (n = 84) received either no medication or flumazenil (0.5 mg i.v.) on completion of endoscopy. Recovery was assessed subjectively. Within 15 min, 83% of those receiving flumazenil were considered ready for discharge compared with only 24% of the control group ( P <0.001). In a second randomised, double‐blind, placebo‐controlled trial of 44 patients, post‐operative recovery was assessed using five objective psychomotor tests. Whereas the placebo group took up to 2 h to recover, those receiving flumazenil recovered fully or returned to near control values within 15 min. Sedoanalgesia ‐ a technique combining adequate local anaesthesia with sedation (using midazolam) ‐ has wide application in urology, and the introduction of flumazenil has major implications for the practice of day‐case surgery.